(t)ide-naive patients without cirrhosis; nucleos(t)ide-naive patients with compensated cirrhosis; and lamivudine-resistant patients. Disease … compared with lamivudine then tenofovir. First-line tenofovir DF strongly dominated first-line entecavir. Giving tenofovir DF … monotherapy immediately after lamivudine resistance developed was less costly and more effective than any other active treatment …

by hepatitis B vaccination, prophylactic lamivudine use in mothers with high viraemia has been proposed. However, the … Taiwanese societal perspective, of administering prophylactic lamivudine to mothers to reduce vertical transmission of hepatitis … controlled trials was conducted to evaluate the efficacy of lamivudine versus placebo. A Markov decision model was constructed in …

effectiveness of adefovir, entecavir, lamivudine, pegylated interferon and telbivudine. Methods: We conducted a cost …

B (CHB) with entecavir compared with lamivudine with adefovir salvage, based primarily on the results of a recent 2-year … clinical data for entecavir and lamivudine beyond 1-year duration and for salvage therapy. Methods: We conducted a cost …-old patients with HBeAg-positive CHB. We evaluated 2 years of treatment with entecavir 0.5mg/day versus lamivudine 100mg/day, plus …

carcinoma. Lamivudine is the only oral antiviral agent approved for the treatment of patients with chronic hepatitis B …. Lamivudine is useful in a wide range of patients with chronic hepatitis B and ongoing viral replication. In patients with … compensated liver disease treated for 52 weeks in multicenter randomized, double-blind clinical studies, lamivudine 100 mg …

developed countries. Two nucleoside analogue reverse transcriptase inhibitors, such as lamivudine and zidovudine, plus a … for initial or second-line treatment. A combination formulation of lamivudine and zidovudine has recently become available …. Combination therapy with lamivudine and zidovudine (as dual therapy or in combination with another nucleoside analogue reverse …